Eaton Vance Management Biomarin Pharmaceutical Inc Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Eaton Vance Management holds 61,432 shares of BMRN stock, worth $4.32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

61,432

Previous 60,881 0.91%

Holding current value

$4.32 Million

Previous $5.05 Million 3.23%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $45,270 - $53,413	551 Added 0.91%	61,432 $5.21 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $1.42 Million - $1.73 Million	-19,925 Reduced 24.66%	60,881 $5.05 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $4.67 Million - $5.82 Million	62,834 Added 349.62%	80,806 $6.23 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $215 - $274	-3 Reduced 0.02%	17,972 $1.53 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $9,421 - $10,769	-126 Reduced 0.7%	17,975 $1.34 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $6,493 - $7,291	86 Added 0.48%	18,101 $1.51 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $224 - $272	-3 Reduced 0.02%	18,015 $1.36 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $41,097 - $51,053	566 Added 3.24%	18,018 $1.58 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $5.43 Million - $9.9 Million	-75,552 Reduced 81.24%	17,452 $1.33 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $804,091 - $1.26 Million	-10,108 Reduced 9.8%	93,004 $11.5 Million
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $9,634 - $13,074	135 Added 0.13%	103,112 $8.71 Million
Q4 2019 Feb 11, 2020	SELL	$64.27 - $86.37 $160,482 - $215,665	-2,497 Reduced 2.37%	102,977 $8.71 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $5,863 - $7,404	-87 Reduced 0.08%	105,474 $7.11 Million
Q2 2019 Aug 16, 2019	SELL	$80.35 - $93.9 $1.65 Million - $1.92 Million	-20,483 Reduced 16.25%	105,561 $9.04 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $2.15 Million - $2.52 Million	-25,582 Reduced 16.87%	126,044 $11.2 Million
Q4 2018 Feb 07, 2019	SELL	$80.14 - $106.07 $75,491 - $99,917	-942 Reduced 0.62%	151,626 $12.9 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $1.86 Million - $2.1 Million	-19,820 Reduced 11.5%	152,568 $14.8 Million
Q2 2018 Aug 10, 2018	SELL	$76.01 - $99.03 $1.23 Million - $1.6 Million	-16,151 Reduced 8.57%	172,388 $16.2 Million
Q1 2018 May 07, 2018	SELL	$77.67 - $92.63 $17.3 Million - $20.6 Million	-222,696 Reduced 54.15%	188,539 $15.3 Million
Q4 2017 Feb 12, 2018	SELL	$80.76 - $95.13 $5.72 Million - $6.74 Million	-70,817 Reduced 14.69%	411,235 $36.7 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $38.9 Million - $45.8 Million	482,052	482,052 $44.9 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Biomarin Pharmaceutical Inc Transaction History